2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

Saved in:

Bibliographic Details
Main Authors:	Ruperto N (Author), Quartier P (Author), Wulffraat N (Author), Woo P (Author), Loy A (Author), Mouy R (Author), Bader-Meunier B (Author), Prakken B (Author), Noseda E (Author), Rordorf C (Author)
Format:	Book
Published:	BMC, 2008-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)
by: Wittkowski H, et al.
Published: (2008)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
by: Kümmerle-Deschner J, et al.
Published: (2008)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
by: Livermore P, et al.
Published: (2008)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
by: De Benedetti Fabrizio, et al.
Published: (2012)

Application of the Yamaguchi criteria for classification of "suspected" systemic juvenile idiopathic arthritis (sJIA)
by: Kumar Sharath, et al.
Published: (2012)

The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA
by: Grant Schulert, et al.
Published: (2024)

Diversity in clinical manifestations of autoinflammatory syndromes
by: Bader-Meunier B, et al.
Published: (2011)

Mesenchymal stem cells and JIA
by: Slaper-Cortenbach I, et al.
Published: (2011)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
by: Espada G, et al.
Published: (2011)

Severe sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
by: Meng Xu, et al.
Published: (2020)

Systemic onset Juvenile Idiopathic Arthritis (SoJIA): a monocentric study of 114 patients
by: Meunier B, et al.
Published: (2011)

Safety of rituximab in children with auto-immune diseases
by: Bader-Meunier B, et al.
Published: (2008)

miR-885-5p Negatively Regulates Warburg Effect by Silencing Hexokinase 2 in Liver Cancer
by: Fei Xu, et al.
Published: (2019)

Subclinical TRAPS treated with canakinumab
by: M. Amatruda, et al.
Published: (2021)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
by: Takada H, et al.
Published: (2011)

Could canakinumab be used for COVID-19?
by: V. A. Otdelenov, et al.
Published: (2020)

Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody
by: Daria D. Vankova, et al.
Published: (2018)

The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study
by: Fabrizio de Benedetti, et al.
Published: (2024)

Comparison of the accuracy of different definitions of clinical remission (CR) and minimal disease activity (MDA) in juvenile idiopathic arthritis (JIA)
by: Davì S, et al.
Published: (2008)

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study
by: McCann L, et al.
Published: (2011)

Outcome of children with panarteritis nodosa: a series of 30 cases
by: Mouy R, et al.
Published: (2011)

LncRNA HOXA-AS2 facilitates prostate cancer progression by inhibiting miR-885-5p to upregulate KDM5B
by: Zhi Yang, et al.
Published: (2022)

Determing an "autoimmune" phenotype in systemic JIA
by: Haas JP, et al.
Published: (2011)

Pediatric systemic lupus erythematosus and human parvovirus B19 infection
by: Quartier P, et al.
Published: (2011)

Development and initial validation of the parent acceptable symptom state in juvenile idiopathic arthritis (JIA)
by: Filocamo G, et al.
Published: (2008)

Treatment of refractory Yao syndrome with canakinumab
by: Caroline J. Brailsford, MS, et al.
Published: (2022)

CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
by: Ye. I. Alekseeva, et al.
Published: (2014)

The journey of canakinumab; on- and off-label indications
by: Daniela Marotto, et al.
Published: (2019)

Jia Zhangke on Jia Zhangke
by: Berry, Michael
Published: (2022)

Jia Zhangke on Jia Zhangke
by: Berry, Michael
Published: (2022)

Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe
by: Alexei A. Grom, et al.
Published: (2024)

Assessment of oral emergency services during COVID-19: a retrospective study of 14,885 cases in Shanghai
by: Jian Wang, et al.
Published: (2023)

Canakinumab and cardiovascular outcomes: results of the CANTOS trial
by: Syed Raza Shah, et al.
Published: (2018)

EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID)
by: T. V. Sleptsova, et al.
Published: (2014)

A meta-analysis to estimate the "real" placebo effect in juvenile idiopathic arthritis (JIA) trials
by: Martini A, et al.
Published: (2011)

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
by: Angel Luis Salcedo-Mingoarranz, et al.
Published: (2023)

Modulation of Inflammation in Heart Failure: The Role of Ziltivekimab and Canakinumab
by: Łukasz Wołowiec, et al.
Published: (2024)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
by: van Wijk Femke, et al.
Published: (2011)

Systemic-onset juvenile rheumatoid arthritis and ANCA-associated glomerulonephritis
by: Belot A, et al.
Published: (2008)

EXPERIENCE OF THE SUCCESSFUL CANAKINUMAB TREATMENT OF A PATIENT WITH UNDIFFERENTIATED AUTOINFLAMMATORY SYNDROME
by: Tatyana V. Sleptsova, et al.
Published: (2016)